Search clinical trials for: anti-PD-1 / PD-L1 monoclonal antibody
Total 132765 results
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Shanghai Zhongshan HospitalRecruiting
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.CompletedIdiopathic Parkinson's DiseaseUnited States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedSolid TumorUnited States
-
Huabo Biopharm Co., Ltd.Recruiting
-
Shanghai Zhongshan HospitalRecruitingHepatocellular CarcinomaChina
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Eli Lilly and CompanyCompletedAdvanced CancerBelgium, United States, Korea, Republic of, Australia, France
-
Pyrotech Therapeutics, Inc.RecruitingLocally Advanced or Metastatic Solid TumorsUnited States
-
Thomas MarronRecruiting
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Squamous Cell, Non-small-cell LungPoland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
UNICANCERFondation ARCActive, not recruitingMelanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaFrance
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.UnknownAdvanced Solid TumorsChina
-
Baodong QinUnknown
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Non-squamous Non-small-cell LungPoland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Guohui LiRecruitingPD-1 | Immune Related Adverse EventsChina
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Merck Sharp & Dohme LLCRecruitingSolid Tumors | Hematologic MalignanciesUnited States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
-
Merck Sharp & Dohme LLCCompletedNon-small Cell Lung CancerChina, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
-
Merck Sharp & Dohme LLCActive, not recruitingBreast CancerJapan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingCarcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Bronchogenic | Lung Disease | Respiratory Tract Disease | Respiratory Tract Neoplasms Nec | Neoplasm, BronchialChina
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompleted
-
Zhongnan HospitalRecruiting
-
Merck Sharp & Dohme LLCRecruitingBladder CancerCanada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCActive, not recruitingTriple Negative Breast NeoplasmsBrazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
-
Merck Sharp & Dohme LLCCompleted
-
Genentech, Inc.Completed
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Hoffmann-La RocheCompletedBladder CancerUnited States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
-
Shanghai Zhongshan HospitalRecruiting
-
Instituto Nacional de Cancerologia de MexicoUnknownNon-Small Cell Lung CancerMexico
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting